Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Karo Bio has been informed by its research partner, Wyeth Pharmaceuticals, that the development of its early-stage atherosclerosis candidate has been discontinued.
Subscribe to our email newsletter
The compound, LXR-623, had been in Phase I testing for the treatment of atherosclerosis. While LXR-623 demonstrated efficacy on biomarkers for atherosclerosis, it had an unfavorable profile for further development.
Per Olof Wallstrom, president of Karo Bio, said: “Unfortunately compounds do fail in the process but this is part of the development of pharmaceuticals. We remain optimistic about LXR as a target for treatment of atherosclerosis and for the prospects for new molecules for development. The learnings generated from the LXR-623 program will be valuable as additional potential compounds move forward.”
Swedish pharmaceutical firm Karo Bio said that the company and Wyeth remain committed to the research partnership and to advancing a new lead compound under the terms of the collaboration, which was recently extended until August 31, 2008.